| 04.04.18 | Pacts and paydays for protein degradation biotechs Arvinas and Kymera

Laden...

6 jaren geleden

Html
Tekst

To view this email as a web page, click here

This week's sponsor is Premier Research.
	Opportunity Knocks: Seizing the Promise of Orphan Drugs Orphan drug developers enjoy more favorable regulatory conditions today than ever. Read our white paper for tips on maximizing this opportunity. Premier Research. It's what we do. Best.

Today's Rundown

Arvinas gains $55M C round as it eyes cancer trials, pipeline work Kymera pens new pact with GSK as protein degradation R&D continues to ramp up Buoyed by long-term organ transplant data, ITBMed bags $67M to advance ex-MedImmune asset [Sponsored] Personalized Medicine Requires Personalized Measurement Terns emerges with all 3 of Lilly’s NASH programs and $30M from Lilly Asia Ventures Sofinnova raises €275M crossover fund to back late-stage firms Eli Lilly ponies up $63M for Sigilon’s diabetes cell therapies Genomic analysis uncovers prevalence of RNA splicing mutations in 33 tumor types #FierceMadness ends in over-the-top ballot stuffing, but we still pick a winner

Featured Story

Arvinas gains $55M C round as it eyes cancer trials, pipeline work

Wednesday, April 4, 2018

Former Fierce 15 winner Arvinas, which has caught the attention of Pfizer and Roche over the last year, has got off a strong $55 million series C as it looks to bring its cancer candidates into the clinic.

This week's sponsor is STEMCELL Technologies.

Kymera pens new pact with GSK as protein degradation R&D continues to ramp up

Wednesday, April 4, 2018

Six months after getting off its series A, Kymera Therapeutics has nabbed a deal with GlaxoSmithKline to collaborate on its platform, although exact details on money and targets remain under wraps.

Buoyed by long-term organ transplant data, ITBMed bags $67M to advance ex-MedImmune asset

Wednesday, April 4, 2018

ITBMed has raised $67 million (€55 million) to advance siplizumab in organ transplant patients. The ex-MedImmune monoclonal antibody impressed in a 10-patient trial, raising hopes that ITBMed can snag a limited, near-term approval before running a pivotal study to expand its use.

[Sponsored] Personalized Medicine Requires Personalized Measurement

Monday, April 2, 2018

How we measure outcomes will evolve from applying one solution to finding an empirical basis for a highly customized application of all of them. Personalized medicine needs a more personalized approach to measurement. Read more.

Terns emerges with all 3 of Lilly’s NASH programs and $30M from Lilly Asia Ventures

Wednesday, April 4, 2018

The hot NASH arena has a new player, Terns Pharmaceuticals, and it has already got three candidates from Eli Lilly, a $30 million series A backed by Lilly Asia Ventures, and a strategy to go after approval in China first.

Sofinnova raises €275M crossover fund to back late-stage firms

Wednesday, April 4, 2018

Sofinnova Partners has raised a €275 million ($340 million) crossover fund. The vehicle sets Sofinnova up to expand beyond its traditional areas of focus and invest in 15 late-stage private and public drug and medical device companies.

Eli Lilly ponies up $63M for Sigilon’s diabetes cell therapies

Wednesday, April 4, 2018

Eli Lilly said last year its insulin business would become "obsolete" if it didn't diversify its diabetes offerings. Now, the Big Pharma is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.

Genomic analysis uncovers prevalence of RNA splicing mutations in 33 tumor types

Tuesday, April 3, 2018

Scientists at H3 Biomedicine published an analysis of Cancer Genome Atlas data showing that RNA splicing mutations appear more frequently and in more types of cancer than previously thought.

#FierceMadness ends in over-the-top ballot stuffing, but we still pick a winner

Wednesday, April 4, 2018

The first rule of ballot stuffing? Don’t overdo it, as it raises red flags. And that’s exactly what 34,035 votes for Brineura in our #FierceMadness drug-name contest did.

This week's sponsor is Sensors Expo.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Resources

[Whitepaper] 2018 Life Sciences Trends

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Presented by: Patheon, part of Thermo Fisher Scientific

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

Presented by: Charles River

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Presented by: Covance

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.